Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax

(2020) Yu-Wen Wang et al.   ANNALS OF HEMATOLOGY

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

(2020) Courtney D. DiNardo et al.   BLOOD

Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Acute Myeloid Leukemia Patients

(2020) Shanshan Pei et al.   Cancer Discovery

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results.

(2020) David Andrew Sallman et al.   JOURNAL OF CLINICAL ONCOLOGY

Venetoclax is safe and efficacious in relapsed/refractory AML

(2020) Chezi Ganzel et al.   LEUKEMIA & LYMPHOMA

Venetoclax and hypomethylating agents in FLT3 ‐mutated acute myeloid leukemia

(2020) Ibrahim Aldoss et al.   AMERICAN JOURNAL OF HEMATOLOGY

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

(2020) Courtney D. DiNardo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients

(2020) Erika Morsia et al.   AMERICAN JOURNAL OF HEMATOLOGY

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

(2020) Courtney D DiNardo et al.   Lancet Haematology

Sensitivity to splicing modulation of BCL2 family genes defines cancer therapeutic strategies for splicing modulators

(2019) Daniel Aird et al.   Nature Communications

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

(2019) Andrew H. Wei et al.   JOURNAL OF CLINICAL ONCOLOGY

Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

(2019) Ibrahim Aldoss et al.   AMERICAN JOURNAL OF HEMATOLOGY

Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents—a multicenter historical prospective study

(2019) Ron Ram et al.   ANNALS OF HEMATOLOGY

How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia

(2019) Brian A. Jonas et al.   LEUKEMIA

Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

(2018) Ibrahim Aldoss et al.   HAEMATOLOGICA

Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

(2018) Ibrahim Aldoss et al.   HAEMATOLOGICA

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

(2018) Courtney D. DiNardo et al.   BLOOD

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia

(2016) Catherine C. Coombs et al.   HAEMATOLOGICA

Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia

(2016) Catherine C. Coombs et al.   HAEMATOLOGICA

Genetic alterations of the cohesin complex genes in myeloid malignancies

(2014) S. Thota et al.   BLOOD